Logo image of CRI.PA

COMPAGNIE CHARGEURS INVEST (CRI.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:CRI - FR0000130692 - Common Stock

9.52 EUR
-0.12 (-1.24%)
Last: 11/21/2025, 7:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CRI. CRI was compared to 15 industry peers in the Industrial Conglomerates industry. CRI may be in some trouble as it scores bad on both profitability and health. CRI has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

CRI had positive earnings in the past year.
CRI had a positive operating cash flow in the past year.
CRI had positive earnings in 4 of the past 5 years.
In multiple years CRI reported negative operating cash flow during the last 5 years.
CRI.PA Yearly Net Income VS EBIT VS OCF VS FCFCRI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

1.2 Ratios

Looking at the Return On Assets, with a value of 0.26%, CRI is doing worse than 66.67% of the companies in the same industry.
With a Return On Equity value of 0.96%, CRI is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
With a Return On Invested Capital value of 5.19%, CRI perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for CRI is below the industry average of 6.68%.
The 3 year average ROIC (4.65%) for CRI is below the current ROIC(5.19%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.26%
ROE 0.96%
ROIC 5.19%
ROA(3y)1.05%
ROA(5y)2.21%
ROE(3y)3.33%
ROE(5y)7.74%
ROIC(3y)4.65%
ROIC(5y)5.48%
CRI.PA Yearly ROA, ROE, ROICCRI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15

1.3 Margins

CRI has a Profit Margin of 0.34%. This is in the lower half of the industry: CRI underperforms 66.67% of its industry peers.
In the last couple of years the Profit Margin of CRI has declined.
CRI has a Operating Margin (6.46%) which is in line with its industry peers.
In the last couple of years the Operating Margin of CRI has remained more or less at the same level.
CRI has a worse Gross Margin (28.51%) than 80.00% of its industry peers.
CRI's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 6.46%
PM (TTM) 0.34%
GM 28.51%
OM growth 3Y1.32%
OM growth 5Y1.18%
PM growth 3Y-37.78%
PM growth 5Y-16.13%
GM growth 3Y3.87%
GM growth 5Y1.23%
CRI.PA Yearly Profit, Operating, Gross MarginsCRI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15 20 25

1

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CRI is destroying value.
CRI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CRI has been increased compared to 5 years ago.
CRI has a better debt/assets ratio than last year.
CRI.PA Yearly Shares OutstandingCRI.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
CRI.PA Yearly Total Debt VS Total AssetsCRI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 1.22, we must say that CRI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.22, CRI is doing worse than 86.67% of the companies in the same industry.
CRI has a debt to FCF ratio of 131.84. This is a negative value and a sign of low solvency as CRI would need 131.84 years to pay back of all of its debts.
CRI has a worse Debt to FCF ratio (131.84) than 73.33% of its industry peers.
CRI has a Debt/Equity ratio of 1.38. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.38, CRI is doing worse than 66.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 131.84
Altman-Z 1.22
ROIC/WACC0.8
WACC6.48%
CRI.PA Yearly LT Debt VS Equity VS FCFCRI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

CRI has a Current Ratio of 1.30. This is a normal value and indicates that CRI is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.30, CRI is not doing good in the industry: 93.33% of the companies in the same industry are doing better.
CRI has a Quick Ratio of 1.30. This is a bad value and indicates that CRI is not financially healthy enough and could expect problems in meeting its short term obligations.
CRI's Quick ratio of 0.86 is on the low side compared to the rest of the industry. CRI is outperformed by 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.86
CRI.PA Yearly Current Assets VS Current LiabilitesCRI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 146.24% over the past year.
CRI shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.59% yearly.
Looking at the last year, CRI shows a small growth in Revenue. The Revenue has grown by 6.67% in the last year.
Measured over the past years, CRI shows a small growth in Revenue. The Revenue has been growing by 3.10% on average per year.
EPS 1Y (TTM)146.24%
EPS 3Y-38.62%
EPS 5Y-14.59%
EPS Q2Q%-146%
Revenue 1Y (TTM)6.67%
Revenue growth 3Y-0.32%
Revenue growth 5Y3.1%
Sales Q2Q%-0.56%

3.2 Future

CRI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.48% yearly.
CRI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.12% yearly.
EPS Next Y46.67%
EPS Next 2Y52.98%
EPS Next 3Y32.48%
EPS Next 5YN/A
Revenue Next Year3.88%
Revenue Next 2Y5.15%
Revenue Next 3Y4.12%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRI.PA Yearly Revenue VS EstimatesCRI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
CRI.PA Yearly EPS VS EstimatesCRI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 79.33, CRI can be considered very expensive at the moment.
66.67% of the companies in the same industry are cheaper than CRI, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.45, CRI is valued quite expensively.
A Price/Forward Earnings ratio of 9.21 indicates a reasonable valuation of CRI.
Based on the Price/Forward Earnings ratio, CRI is valued a bit cheaper than 80.00% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of CRI to the average of the S&P500 Index (34.46), we can say CRI is valued rather cheaply.
Industry RankSector Rank
PE 79.33
Fwd PE 9.21
CRI.PA Price Earnings VS Forward Price EarningsCRI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CRI is valued a bit cheaper than 73.33% of the companies in the same industry.
73.33% of the companies in the same industry are cheaper than CRI, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 74.05
EV/EBITDA 7.04
CRI.PA Per share dataCRI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

CRI's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
CRI's earnings are expected to grow with 32.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.7
PEG (5Y)N/A
EPS Next 2Y52.98%
EPS Next 3Y32.48%

1

5. Dividend

5.1 Amount

CRI has a Yearly Dividend Yield of 1.35%. Purely for dividend investing, there may be better candidates out there.
CRI's Dividend Yield is slightly below the industry average, which is at 3.61.
Compared to an average S&P500 Dividend Yield of 2.42, CRI's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 1.35%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
CRI.PA Yearly Dividends per shareCRI.PA Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2025 0.5 1 1.5

5.3 Sustainability

CRI pays out 128.00% of its income as dividend. This is not a sustainable payout ratio.
DP128%
EPS Next 2Y52.98%
EPS Next 3Y32.48%
CRI.PA Yearly Income VS Free CF VS DividendCRI.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M
CRI.PA Dividend Payout.CRI.PA Dividend Payout, showing the Payout Ratio.CRI.PA Dividend Payout.PayoutRetained Earnings

COMPAGNIE CHARGEURS INVEST

EPA:CRI (11/21/2025, 7:00:00 PM)

9.52

-0.12 (-1.24%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryIndustrial Conglomerates
Earnings (Last)11-05 2025-11-05
Earnings (Next)02-11 2026-02-11/amc
Inst Owners5.35%
Inst Owner ChangeN/A
Ins Owners64.2%
Ins Owner ChangeN/A
Market Cap236.95M
Revenue(TTM)727.50M
Net Income(TTM)2.50M
Analysts75
Price Target12.41 (30.36%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.35%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP128%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.19%
PT rev (3m)-6.95%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-13.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.07%
Revenue NY rev (3m)-2.34%
Valuation
Industry RankSector Rank
PE 79.33
Fwd PE 9.21
P/S 0.33
P/FCF 74.05
P/OCF 10.13
P/B 0.91
P/tB N/A
EV/EBITDA 7.04
EPS(TTM)0.12
EY1.26%
EPS(NY)1.03
Fwd EY10.86%
FCF(TTM)0.13
FCFY1.35%
OCF(TTM)0.94
OCFY9.88%
SpS29.23
BVpS10.49
TBVpS-1.46
PEG (NY)1.7
PEG (5Y)N/A
Graham Number5.32
Profitability
Industry RankSector Rank
ROA 0.26%
ROE 0.96%
ROCE 7.08%
ROIC 5.19%
ROICexc 6.18%
ROICexgc 13.23%
OM 6.46%
PM (TTM) 0.34%
GM 28.51%
FCFM 0.44%
ROA(3y)1.05%
ROA(5y)2.21%
ROE(3y)3.33%
ROE(5y)7.74%
ROIC(3y)4.65%
ROIC(5y)5.48%
ROICexc(3y)5.7%
ROICexc(5y)7.48%
ROICexgc(3y)13.2%
ROICexgc(5y)17.03%
ROCE(3y)6.37%
ROCE(5y)7.53%
ROICexgc growth 3Y-6.3%
ROICexgc growth 5Y2.48%
ROICexc growth 3Y-7.54%
ROICexc growth 5Y-2.79%
OM growth 3Y1.32%
OM growth 5Y1.18%
PM growth 3Y-37.78%
PM growth 5Y-16.13%
GM growth 3Y3.87%
GM growth 5Y1.23%
F-Score7
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 131.84
Debt/EBITDA 4.62
Cap/Depr 65.16%
Cap/Sales 2.78%
Interest Coverage 250
Cash Conversion 30%
Profit Quality 128%
Current Ratio 1.3
Quick Ratio 0.86
Altman-Z 1.22
F-Score7
WACC6.48%
ROIC/WACC0.8
Cap/Depr(3y)59.11%
Cap/Depr(5y)54.94%
Cap/Sales(3y)2.51%
Cap/Sales(5y)2.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)146.24%
EPS 3Y-38.62%
EPS 5Y-14.59%
EPS Q2Q%-146%
EPS Next Y46.67%
EPS Next 2Y52.98%
EPS Next 3Y32.48%
EPS Next 5YN/A
Revenue 1Y (TTM)6.67%
Revenue growth 3Y-0.32%
Revenue growth 5Y3.1%
Sales Q2Q%-0.56%
Revenue Next Year3.88%
Revenue Next 2Y5.15%
Revenue Next 3Y4.12%
Revenue Next 5YN/A
EBIT growth 1Y57.72%
EBIT growth 3Y1%
EBIT growth 5Y4.32%
EBIT Next Year118.91%
EBIT Next 3Y41.15%
EBIT Next 5YN/A
FCF growth 1Y109.04%
FCF growth 3Y-17.92%
FCF growth 5Y170%
OCF growth 1Y241.82%
OCF growth 3Y-11.82%
OCF growth 5Y11.78%

COMPAGNIE CHARGEURS INVEST / CRI.PA FAQ

What is the ChartMill fundamental rating of COMPAGNIE CHARGEURS INVEST (CRI.PA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CRI.PA.


Can you provide the valuation status for COMPAGNIE CHARGEURS INVEST?

ChartMill assigns a valuation rating of 4 / 10 to COMPAGNIE CHARGEURS INVEST (CRI.PA). This can be considered as Fairly Valued.


What is the profitability of CRI stock?

COMPAGNIE CHARGEURS INVEST (CRI.PA) has a profitability rating of 3 / 10.


What is the financial health of COMPAGNIE CHARGEURS INVEST (CRI.PA) stock?

The financial health rating of COMPAGNIE CHARGEURS INVEST (CRI.PA) is 1 / 10.


Can you provide the expected EPS growth for CRI stock?

The Earnings per Share (EPS) of COMPAGNIE CHARGEURS INVEST (CRI.PA) is expected to grow by 46.67% in the next year.